Should I buy or sell Theseus Pharmaceuticals stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Theseus Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" THRX shares. View THRX analyst ratings or view top-rated stocks .

What is Theseus Pharmaceuticals' stock price target for 2024?

4 brokerages have issued 1-year target prices for Theseus Pharmaceuticals' stock. Their THRX share price targets range from $4.00 to $9.00. On average, they predict the company's share price to reach $6.75 in the next year. This suggests a possible upside of 66.3% from the stock's current price. View analysts price targets for THRX or view top-rated stocks among Wall Street analysts .

How were Theseus Pharmaceuticals' earnings last quarter?

Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) released its quarterly earnings results on Monday, November, 15th. The company reported ($5.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.23) by $4.93.

When did Theseus Pharmaceuticals IPO?

Theseus Pharmaceuticals (THRX) raised $150 million in an initial public offering (IPO) on Thursday, October 7th 2021. The company issued 10,000,200 shares at $14.00-$16.00 per share.

NASDAQ:THRX

Theseus Pharmaceuticals (THRX) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Free THRX Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $4.06
▼
$4.06
50-Day Range: $4.06
▼
$4.07
52-Week Range: $2.05
▼
$12.37

Volume: N/A
Average Volume: 592,167 shs
Market Capitalization: $179.57 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.75

Stock Analysis Analyst Forecasts Earnings Headlines Insider Trades Ownership Short Interest Social Media

Get Theseus Pharmaceuticals alerts:

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Theseus Pharmaceuticals Stock (NASDAQ:THRX)

Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors. The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. As of February 14, 2024, Theseus Pharmaceuticals, Inc. operates as a subsidiary of Concentra Biosciences, LLC.

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

THRX Stock News Headlines

February 14, 2024 | finance.yahoo.com

Theseus Pharmaceuticals Announces Closing of Tender Offer

February 14, 2024 | prnewswire.com

Theseus Pharmaceuticals Announces Closing of Tender Offer

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

January 30, 2024 | finance.yahoo.com

Concentra Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Theseus Pharmaceuticals

January 20, 2024 | stockhouse.com

SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates CSTR, THRX, GRCL, ROVR

December 31, 2023 | businesswire.com

THESEUS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ...

December 29, 2023 | finance.yahoo.com

Is Theseus Pharmaceuticals (THRX) Stock a Solid Choice Right Now?

December 27, 2023 | markets.businessinsider.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DSKE, KRTX, THRX, CONN

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

December 22, 2023 | marketwatch.com

Theseus Pharmaceuticals Shares Rise 9.3% on Deal to Be Acquired by Concentra

December 22, 2023 | marketwatch.com

Concentra Biosciences to Acquire Theseus Pharmaceuticals for $3.90 to $4.05/Shr

December 22, 2023 | markets.businessinsider.com

Theseus Pharma To Acquire Concentra Biosciences For $4.05/Shr In Cash

December 22, 2023 | tmcnet.com

THRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Theseus Pharmaceuticals, Inc. Is Fair to Shareholders

December 22, 2023 | finance.yahoo.com

Theseus Pharmaceuticals Enters into Agreement to Be Acquired by Concentra Biosciences for between $3.90 and $4.05 in Cash per Share Plus a Contingent Value Right

November 27, 2023 | msn.com

UP Fintech, Cerence, Irsa Inversiones Y Representaciones among premarket gainers pack

November 27, 2023 | markets.businessinsider.com

Theseus Pharma To Evaluate Expression Of Interest From Foresite, OrbiM And Proposal From Concentra

November 27, 2023 | finance.yahoo.com

Theseus Pharmaceuticals Confirms Receipt of Unsolicited Expression of Interest from Foresite Capital, LLC and OrbiMed Advisors LLC and Unsolicited Proposal from Concentra Biosciences LLC

November 14, 2023 | finance.yahoo.com

Theseus Pharmaceuticals Inc (THRX) Explores Strategic Alternatives Amidst Workforce Reduction

November 14, 2023 | bizjournals.com

Two years after IPO, Theseus Pharmaceuticals lays off most its staff, explores sale

November 14, 2023 | benzinga.com

Thinking about buying stock in Theseus Pharmaceuticals, Vuzix, Jaguar Global Growth, Fisker, or Cardio Diagnostics Holdings?

November 13, 2023 | marketwatch.com

Theseus Pharmaceuticals Shares Rise 35% on Workforce Reduction, Strategic Alternatives Consideration

November 13, 2023 | msn.com

Theseus Pharmaceuticals explores strategic options; cuts workforce by 72%

November 13, 2023 | finance.yahoo.com

Theseus Pharmaceuticals Announces Process to Explore Strategic Alternatives

November 7, 2023 | morningstar.com

Theseus Pharmaceuticals Inc THRX

November 7, 2023 | finance.yahoo.com

Theseus Pharmaceuticals to Participate in the Stifel 2023 Healthcare Conference

October 9, 2023 | finance.yahoo.com

Theseus Pharmaceuticals (NASDAQ:THRX) Is In A Good Position To Deliver On Growth Plans

September 29, 2023 | msn.com

Theseus Pharmaceuticals: Picking Up The Pieces After A Lead Failure

See More Headlines

Receive THRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Theseus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/15/2021
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:THRX
CUSIP: N/A
CIK: 1745020
Web: theseusrx.com
Phone: 857-400-9491
Fax: N/A
Employees: 38
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $6.75
High Stock Price Target: $9.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +66.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.34)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-50,610,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -24.84%
Return on Assets: -23.64%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 29.93
Quick Ratio: 29.93

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.36 per share
Price / Book: 0.76

Miscellaneous

Outstanding Shares: 44,230,000
Free Float: 23,575,000
Market Cap: $179.57 million
Optionable: Optionable
Beta: 3.98

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Iain D. Dukes DPHIL (Age 66)
M.A., Co-Founder & Chairman
Comp: $67.28k
Mr. Bradford D. Dahms (Age 36)
President, CFO & Director
Comp: $480.95k
Ms. Kristine Callahan CPA
VP & Controller

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

THRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Theseus Pharmaceuticals stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Theseus Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" THRX shares.
View THRX analyst ratings or view top-rated stocks.
What is Theseus Pharmaceuticals' stock price target for 2024?: 4 brokerages have issued 1-year target prices for Theseus Pharmaceuticals' stock. Their THRX share price targets range from $4.00 to $9.00. On average, they predict the company's share price to reach $6.75 in the next year. This suggests a possible upside of 66.3% from the stock's current price.
View analysts price targets for THRX or view top-rated stocks among Wall Street analysts.
How were Theseus Pharmaceuticals' earnings last quarter?: Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) released its quarterly earnings results on Monday, November, 15th. The company reported ($5.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.23) by $4.93.
When did Theseus Pharmaceuticals IPO?: Theseus Pharmaceuticals (THRX) raised $150 million in an initial public offering (IPO) on Thursday, October 7th 2021. The company issued 10,000,200 shares at $14.00-$16.00 per share.

This page (NASDAQ:THRX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Theseus Pharmaceuticals (THRX) Stock Price, News & Analysis

About Theseus Pharmaceuticals Stock (NASDAQ:THRX)

THRX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

THRX Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info